Professor John M Goldman DM, FRCP,FRCPath, FMedSci

Senior Research Investigator

Division of Investigative Science

Imperial College London, UK

Professor John M. Goldman has a long standing interest in the biology and therapy of chronic myeloid leukemia (CML).  He was until 2004 Chairman of the Department of Haematology at Imperial College London, Director of the Leukaemia Research Fund Centre for Adult Leukaemia and Clinical Director of the Haematology Department at the Hammersmith Hospitals NHS Trust. Thereafter he took up a 2-year appointment as Fogarty Scholar at the National Institutes of Health in Bethesda USA.  He is now active as Emeritus Professor of Haematology at Imperial College London and Medical Director of the Anthony Nolan Trust.  He is editor of Bone Marrow Transplantation, a former editor of The Haematology Journal, and an associate editor of the European Journal of Haematology. He is also an editorial board member of numerous other journals and, during the course of his career, has published over 800 papers in peer-reviewed journals. As well as being the founding president of the British Society for Blood and Marrow Transplantation, he is a former president of the International Society for Experimental Hematology, the European Group for Blood and Marrow Transplantation and the European Hematology Association.

Professor Goldman was the first to autograft patients with CML using peripheral blood stem cells and started allogeneic stem cell transplant for CML in 1980. He pioneered the use of unrelated donors for transplanting CML patients and developed PCR technology for monitoring residual disease. He confirmed the preclinical efficacy of the original tyrosine kinase inhibitor (STI571, now imatinib) in 1997 and first used it in the clinic in 1999. Thereafter he has been involved in development of second generation TKIs, notably dasatinib and nilotinib.

Jerald P. Radich, M.D., is a Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and is Professor of Medicine at the University of Washington.  He is the Medical Director of the Research Trials Office at the FHCRC, the co-chair of Leukemia Biology for the Southwest Oncology Group, and is the co-chair of the NCI/Cooperartive Group Leukemia Steering Committee. He belongs to the National Cancer Care Network and EuroLeukemiaNet CML committees. Dr. Radich’s main research interest concerns the genetics of leukemia, and the use of and development of modern molecular biology techniques towards early detection of leukemia.

Professor Timothy P. Hughes, MD, FRACP, FRCPA

Timothy P. Hughes, MD, FRACP, FRCPA, is Head of the Department of Haematology at SA Pathology, RAH site, and Consultant Haematologist at the Royal Adelaide Hospital. He is also Clinical  Professor of Medicine at the University of Adelaide and holds a Practitioner Fellowship from the National Health and Medical Research Council. His clinical interests include chronic leukaemias and myeloproliferative disorders. His current research interests focus are in molecular monitoring for leukaemias, clinical resistance to targeted therapies in leukaemia and the development of assays to predict response and resistance to targeted agents. He has published over 100 articles in peer-reviewed journals. He is a member of the Haematology Society of Australia and New Zealand, for which he served as President from 2001 to 2003, and the Australasian Leukaemia and Lymphoma Group, for which he served as a Director from 1999-2004 and as Vice-Chairman in 2003-4.  In 2006 Professor Hughes was awarded the RACP Eric Susman Prize for the most outstanding contribution to the knowledge of any branch of internal medicine by a member of the College of Physicians.

Prof. Dr. Hemant Malhotra,  MD, FRCP (London), FRCP (Edinburgh), FACP (USA), MNAMS, FICP, FUICC, FIMSA

Professor & Head, Department of Medical Oncology, Sriram Cancer Center,  Mahatma Gandhi Medical College Hospital, Jaipur.

Dr. Hemant Malhotra is presently Professor & Head, Department of Medical Oncology at the Sriram Cancer Center of the Mahatma Gandhi College Hospital, Jaipur. Since superannuating after more than three decades of government service where he was the PHOD, Department of Medicine and Head of the division of Medical Oncology at the Birla Cancer Center, SMS Medical College, Jaipur, he now working full time at the MGMCH. The Mahatma Gandhi Medical College Hospital is 1400 bedded, one of the leading tertiary care teaching and patient care center of North India, and the largest in the private sector.

Dr. Malhotra graduated and post-graduated at the top of his batch from the SMS Medical College and after fellowships at Tata Memorial Cancer Center, Mumbai (1989 to 1991); Cornell Medical Center, New York and Memorial Sloan Kettering Cancer Center, New York, set up the Medical Oncology division in the department of Medicine at the SMS Hospital in 1991, the first in the state of Rajasthan. He also established a Bone Marrow Transplantation Unit at the SMS and his team has successfully done the first-ever autologous bone marrow transplantation in the state of Rajasthan. Regular autologous and allogeneic Stem Cell Transplantations are now being done in the unit.

Dr. Malhotra has more than three decades of treating cancer patients in the state of Rajasthan is a well-recognized and respected teacher. Many of his students are now senior medical oncologists spread all over the country and heading their own departments.

He is an internationally and nationally recognized medical oncologist and was the India, Pakistan & Bangladesh representative to the European Society for Medical Oncology (ESMO) from 2006 to 2008. He is also ESMO board certified in medical oncology. He is an advisor/consultant/referee/committee member for oncology to several Government of India bodies and head the ICMR committee for formulation of guidelines for multiple myeloma. He serves on the Specialty Expert Committee on Hematology & Oncology of the Drug Controller General of India. He has served on the National Oncology SAE Committee of the Drug Controller General of India, Government of India. He has been an invited consultant to the WHO on guideline development for bio-similar oncology molecules.

Dr. Malhotra has to his credit more than 200 international and national publications and presentations and is an office bearer and member of many international and national societies and organizations. He is the lead author of a chapter on Chronic Leukemia in the Oxford Text book of Oncology. He is the Immediate Past President of the Indian Society of Medical & Pediatric Oncology (ISMPO). He is one of the founder members & Head of
the Hematological Cancers Committee of the Indian Cooperative Oncology Network (ICON). 

Dr. Malhotra is keenly interested in clinical research and has completed more than 40 investigator initiated and industry sponsored pivotal clinical trial as Principal Investigator. Dr. Malhotra has investigator-initiated trials and projects in several diseases, especially Chronic Myeloid Leukemia. He is also on the Board of Advisors of the International CML Foundation and is the national representative to the iCMLf from India. Dr. Malhotra has been the Joint Secretary of the Ethic Committee of the SMS Medical College since inception till 2010 and has been instrumental in drafting the SOPs of the EC. He has also been a Member of the Ethics Committee at the Bhagwan Mahaveer Cancer Hospital in Jaipur.

Amongst his recent honors, Dr. Malhotra was awarded the International Chronic Myeloid Leukemia Prize for outstanding work in CML in emerging regions in Miami, USA in 2018. He was also invited to Chair and speak at the 62nd Annual Conference of the American Society of Hematology (ASH) organized at Orlando, USA in the first week of December 2019, the only physicians from the whole country to be give this honor.